Overview

• Trump sent letters on July 31 to 17 major pharmaceutical companies demanding U.S. prices match the lowest rates paid in other developed countries by September 29, 2025.
• The push follows his Most Favored Nations executive order, which ties American prescription drug costs to global low-price benchmarks under an America First framework.
• Health policy experts and social media commentators have ridiculed his promise of 500–1,500% price cuts as preposterous and lacking statistical basis.
• The White House has threatened to “deploy every tool” against any company that refuses to comply while HHS drafts regulations to enforce the new pricing model.
• Critics warn that the administration may face swift legal challenges over its authority to impose such drastic global-parity mandates.